Enzo Biochem, Inc. · New York, NY United States (NYSE: ENZ)
Key Enzo Biochem, Inc. Financials
| Company Type | Public -(NYSE: ENZ) Headquarters |
|---|---|
| Fiscal Year-End | July |
| 2011 Sales (mil.) | $102.0 |
| 2011 Employees | 606 |
Enzo Biochem, Inc. Stock Quote (NYSE: ENZ)
| Latest 02/15/12 16:02:56 EST | Change ($) | Change (%) | High | Low |
|---|---|---|---|---|
| $2.86 |  -0.040 | -1.380 | $2.92 | $2.82 |
Quotes delayed 15 minutes for NASDAQ, 20 minues for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions. |
Enzo Biochem, Inc. Income Statement
| Jul 11 | Jul 10 | Jul 09 | |
| Revenue | 102.0 | 97.1 | 89.6 |
| Cost of Goods Sold | 53.8 | 52.1 | 53.1 |
| Gross Profit | 48.2 | 45.0 | 36.5 |
| Gross Profit Margin | 47.3% | 46.3% | 40.8% |
| SG&A Expense | 48.9 | 52.1 | 45.5 |
| Depreciation & Amortization | 4.5 | 4.3 | 3.5 |
| Operating Income | (12.9) | (22.1) | (23.5) |
| Operating Margin | -12.7% | -22.7% | -26.2% |
| Nonoperating Income | 0.1 | (0.2) | -- |
| Nonoperating Expenses | 0.0 | 0.0 | -- |
| Income Before Taxes | (12.8) | (22.3) | (23.5) |
| Income Taxes | 0.1 | (0.0) | (0.1) |
| Net Income After Taxes | (13.0) | (22.2) | (23.4) |
| Continuing Operations | (13.0) | (22.2) | (23.6) |
| Discontinued Operations | -- | -- | -- |
| Total Operations | (13.0) | (22.2) | (23.6) |
| Total Net Income | (13.0) | (22.2) | (23.6) |
| Net Profit Margin | -12.7% | -22.9% | -26.3% |
| Diluted EPS from Total Net Income | (0.34) | (0.59) | (0.63) |
| Dividends per Share | -- | -- | -- |
All amounts in millions of US Dollars except per share amounts.
Enzo Biochem, Inc. Balance Sheet
| Assets | Jul 11 | Jul 10 | Jul 09 |
| Current Assets | |||
| Cash | 14.2 | 8.8 | 6.9 |
| Net Receivables | 15.2 | 13.0 | 12.5 |
| Inventories | 9.3 | 8.9 | 9.3 |
| Other Current Assets | 12.7 | 27.1 | 45.8 |
| Total Current Assets | 51.4 | 57.7 | 74.5 |
| Net Fixed Assets | 10.3 | 11.9 | 11.3 |
| Other Noncurrent Assets | 47.7 | 45.6 | 47.3 |
| Total Assets | 109.5 | 115.2 | 133.1 |
| Liabilities | Jul 11 | Jul 10 | Jul 09 |
| Current Liabilities | |||
| Accounts Payable | 7.9 | 6.5 | 4.2 |
| Short-Term Debt | -- | -- | -- |
| Other Current Liabilities | 9.9 | 9.1 | 9.7 |
| Total Current Liabilities | 17.7 | 15.6 | 13.9 |
| Long-Term Debt | -- | -- | -- |
| Other Noncurrent Liabilities | 3.0 | 2.7 | 2.4 |
| Total Liabilities | 20.8 | 18.2 | 16.3 |
| Shareholder's Equity | |||
| Preferred Stock Equity | 0.0 | 0.0 | 0.0 |
| Common Stock Equity | 88.7 | 97.0 | 116.8 |
| Total Equity | 88.7 | 97.0 | 116.8 |
| Shares Outstanding (thou.) | 38,595.8 | 38,158.9 | 38,589.9 |
All amounts in millions of US Dollars except per share amounts.
Enzo Biochem, Inc. Cash Flow Statement
| Jul 11 | Jul 10 | Jul 09 | |
| Net Operating Cash Flow | (8) | (13) | (11) |
| Net Investing Cash Flow | 13.5 | 15.3 | (60.2) |
| Net Financing Cash Flow | (0.1) | 0.0 | 0.3 |
| Net Change in Cash | 5.4 | 1.8 | (71.4) |
| Depreciation & Amortization | 4.5 | 4.3 | 3.5 |
| Capital Expenditures | (1.2) | (3.3) | (2.7) |
| Cash Dividends Paid |
All amounts in millions of US Dollars except per share amounts.